HALOZYME THERAPEUTICS COMPLETES ENROLLMENT OF CHEMOPHASE TRIAL

Halozyme Therapeutics has completed patient enrollment for its Chemophase Phase I clinical trial. Chemophase is a novel investigational recombinant therapeutic being developed to enhance the delivery of chemotherapy.

The initial clinical protocol for Chemophase was designed to evaluate a single intravesical (into the bladder) administration of Chemophase along with the widely used anticancer drug mitomycin in patients with superficial bladder cancer. The study enrolled five patients with superficial bladder cancer. The objectives of the study were to determine the safety, tolerability and pharmacokinetics of Chemophase administered intravesically with mitomycin.